ABSTRACT
The spectrum of treatment options for benign prostatic hyperplasia (BPH) is matched by the spectrum of disease severity. New medications and minimally invasive modalities offer a greater range of choices to the urologist and the patient. This does not make treatment planning any easier. Despite these innovations the natural history of the condition with or without intervention is still unclear and can only be inferred from a number of studies. As BPH is rarely life-threatening, management is focused on quality of life. Provided it is safe to avoid surgery, watchful waiting (WW) can be offered to patients who are not bothered much by their symptoms.
